The disparity in access to healthcare between women and men around the world is often talked about, but has never been given a dollar value – until now.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh